Calamos Advisors
SMMT icon

Calamos Advisors’s Summit Therapeutics SMMT Stock Holding History

Calamos Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,628
Closed -$385K – 993
2025
Q3 		$385K Sell
18,628
-4,489
-19% -$109K ﹤0.01% 791
2025
Q2 		$492K Sell
23,117
-860
-4% -$19.6K ﹤0.01% 749
2025
Q1 		$463K Buy
23,977
+156
+0.7% +$3.13K ﹤0.01% 725
2024
Q4 		$425K Sell
23,821
-22,926
-49% -$444K ﹤0.01% 748
2024
Q3 		$1.02M Buy
+46,747
New +$654K ﹤0.01% 665

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCMH
Polymer Capital Management (HK) Hong Kong $1.16B AUM 135.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Calamos Advisors's SMMT Position: Q4 2025 in Review

Calamos Advisors sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 18,628 shares — an estimated $385K sold.

Calamos Advisors first reported a position in SMMT in Q3 2024 and held it in 5 quarters. The position peaked at $1.02M in Q3 2024. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

  • Calamos Advisors reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Calamos Advisors sold 18,628 Summit Therapeutics shares in Q4 2025, an estimated $385K.
  • Calamos Advisors first reported a position in Summit Therapeutics in Q3 2024 and held it in 5 quarters.
  • Calamos Advisors's Summit Therapeutics position peaked at $1.02M in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on Calamos Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.